Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend) Dosing: What Clinics Prescribe and What to Expect

Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend) Dosing: What Clinics Prescribe and What to Expect (2026)

Key Takeaways

• The Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend is not FDA-approved and available for research purposes only
• Research protocols typically employ doses of 100-300 mcg per component, administered subcutaneously 1-3 times daily^[1]
• The blend combines three growth hormone secretagogues with molecular weights of 5,135.9 Da (tesamorelin), 3,647.28 Da (CJC-1295), and 2,332.67 Da (ipamorelin)^[2]
• Titration protocols in research settings typically start at 50% of target dose and escalate over 2-4 weeks
• Subcutaneous injection using 29-31 gauge insulin needles is the standard administration route
• Medical supervision is essential due to the research-only status and potential growth hormone axis effects

What Is Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend)?

The Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend represents a research formulation combining three distinct growth hormone secretagogues with complementary mechanisms of action. Tesamorelin (CAS: 218949-48-5) functions as a growth hormone-releasing hormone (GHRH) analog with 44 amino acids, while CJC-1295 without DAC (CAS: 863288-34-0) acts as a modified GHRH with enhanced stability and a plasma half-life of approximately 30 minutes.^[3] Ipamorelin (CAS: 170851-70-4) operates through the ghrelin receptor (GHS-R1a) pathway, providing a pentapeptide structure that promotes calcium mobilization and cAMP signaling.^[4]

This research blend is not FDA-approved for therapeutic use and remains available exclusively for investigational purposes. The 12mg total formulation typically contains equal proportions of each peptide component (4mg each), though specific ratios may vary between research protocols. Understanding proper dosing protocols becomes critical for researchers working with this multi-component system, as each peptide exhibits distinct pharmacokinetic profiles and receptor binding affinities that influence overall dosing strategies.

Standard Dosing Protocols

Research protocols for the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend vary significantly based on study objectives and population characteristics. Individual component dosing from published research provides the foundation for blend protocols: tesamorelin studies have employed doses ranging from 1-2 mg daily in HIV-associated lipodystrophy trials (NCT00131014),^[5] while CJC-1295 without DAC research has utilized 30 mcg/kg to 60 mcg/kg doses administered 1-3 times daily.^[6] Ipamorelin research protocols typically range from 200-300 mcg administered 2-3 times daily, with peak growth hormone response occurring 15-30 minutes post-injection.^[7]

The combined blend approach requires careful consideration of synergistic effects and potential receptor saturation. Most research facilities employing this blend utilize starting doses of 100-150 mcg per component (300-450 mcg total blend dose) administered once daily via subcutaneous injection. Advanced protocols may escalate to 200-300 mcg per component (600-900 mcg total) divided into 2-3 daily administrations, particularly when investigating peak growth hormone response patterns.^[8]

Titration Schedules

Research protocols employing the Tesamorelin, CJC-1295 (no DAC), Ipamorelin blend typically implement gradual dose escalation to optimize tolerability and assess dose-response relationships. The standard titration approach begins at 50% of the target maintenance dose, with weekly increases of 25-50 mcg per component based on growth hormone response measurements and adverse event monitoring.^[9] This conservative escalation pattern accounts for the cumulative effects of the three-peptide combination and allows researchers to identify optimal dosing thresholds for individual subjects.

Clinical research facilities commonly employ a 4-week titration protocol that balances rapid dose optimization with safety monitoring. Week 1 typically begins with 50-75 mcg per component (150-225 mcg total blend), administered as a single subcutaneous injection 30 minutes before bedtime to maximize endogenous growth hormone pulse synchronization.^[10] Week 2 escalation increases each component by 25-50 mcg, bringing total blend doses to 225-375 mcg daily, while maintaining bedtime administration timing.

Advanced research protocols may implement split-dosing schedules beginning in week 3, dividing the total daily dose into morning (40% of total) and bedtime (60% of total) administrations. This approach leverages the natural circadian rhythm of growth hormone secretion while maintaining consistent peptide exposure throughout the 24-hour period.^[11]

Administration Method

Subcutaneous injection remains the standard administration route for the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend, utilizing 29-31 gauge insulin needles with 0.5-1.0 mL capacity syringes. The injection technique requires a 45-90 degree angle depending on subcutaneous tissue thickness, with needle penetration depth of 4-6 mm for optimal peptide absorption.^[12] Preferred injection sites include the abdominal region (2 inches from navel), anterior thigh (middle third), and posterior upper arm, with systematic rotation between sites to prevent lipodystrophy and maintain consistent absorption rates.

Reconstitution protocols for the 12mg blend typically employ 2-3 mL of bacteriostatic water (0.9% benzyl alcohol), yielding final concentrations of 4-6 mg/mL total peptide content. The reconstituted solution requires gentle mixing without vigorous shaking to preserve peptide integrity, followed by immediate refrigeration at 36-46°F (2-8°C).^[13] Reconstituted peptide maintains stability for 14-21 days under proper storage conditions, though research protocols often specify single-use vials to eliminate contamination risks.

Injection timing considerations significantly impact growth hormone response patterns and research outcomes. Bedtime administration (30-60 minutes before sleep) aligns with natural growth hormone pulse patterns and maximizes synergistic effects between the three peptide components.^[14] For split-dosing protocols, morning injections should occur 30 minutes before breakfast on an empty stomach, while evening doses maintain the pre-bedtime timing. Fasting periods of 2-3 hours before and 1 hour after injection optimize peptide absorption and minimize interference from food-induced insulin responses.

Storage requirements extend beyond simple refrigeration, encompassing protection from light exposure and temperature fluctuations that can degrade peptide bonds. Lyophilized powder maintains stability for 24-36 months when stored at -4°F (-20°C), while reconstituted solutions require consistent 36-46°F (2-8°C) storage with minimal temperature variation.^[15] Research facilities typically employ temperature monitoring systems with alarms to ensure peptide integrity throughout study durations.

Dosing by Use Case

Growth Hormone Response Studies

Research investigating acute growth hormone response to the blend typically employs single doses of 200-400 mcg per component (600-1200 mcg total), administered subcutaneously with blood sampling at 15, 30, 60, and 120-minute intervals post-injection.^[16] Peak growth hormone concentrations generally occur 30-45 minutes after administration, with levels returning to baseline within 3-4 hours. These protocols often utilize crossover designs comparing the blend to individual peptide components at equivalent molar concentrations.

Dose-response studies have identified optimal ranges of 150-250 mcg per component for maximal growth hormone stimulation without receptor saturation effects. Higher doses (>300 mcg per component) may produce diminishing returns due to GHRH and ghrelin receptor downregulation, particularly with repeated administration over 7-14 day periods.^[17]

Metabolic Research Applications

Long-term metabolic studies utilizing the blend typically implement maintenance doses of 100-200 mcg per component administered twice daily (morning and bedtime) for durations of 12-24 weeks. These protocols focus on body composition changes, insulin sensitivity modifications, and lipid profile alterations associated with sustained growth hormone axis stimulation.^[18] Research subjects undergo comprehensive metabolic assessments including DEXA scans, oral glucose tolerance tests, and lipid panels at 4-week intervals.

Split dosing protocols for metabolic research often employ asymmetric distribution: 30% of daily dose in the morning (60-90 minutes before breakfast) and 70% at bedtime to optimize both metabolic signaling and sleep-associated growth hormone release.^[19] Total daily doses typically range from 400-800 mcg blend (133-267 mcg per component) based on subject body weight and baseline growth hormone status.

Sleep Quality Investigations

Sleep research protocols utilizing the blend focus exclusively on bedtime administration, with doses ranging from 300-600 mcg total blend (100-200 mcg per component) given 30-60 minutes before intended sleep onset.^[20] These studies typically employ polysomnography monitoring to assess slow-wave sleep duration, sleep efficiency, and growth hormone pulse amplitude during the first 3-4 hours of sleep.

Research has identified optimal dosing windows of 150-200 mcg per component for sleep quality enhancement without causing sleep fragmentation or early morning awakening. Higher doses (>250 mcg per component) may paradoxically impair sleep quality due to excessive growth hormone stimulation and associated metabolic activation.^[21]

Factors That Affect Dosing

Body weight significantly influences optimal dosing for the Tesamorelin, CJC-1295 (no DAC), Ipamorelin blend, with research protocols commonly employing weight-based calculations of 2-4 mcg/kg per component for maintenance dosing.^[22] Subjects weighing less than 70 kg typically require 20-30% dose reductions to achieve comparable growth hormone responses, while those exceeding 100 kg may need 15-25% dose increases. Body mass index (BMI) considerations become particularly relevant above 30 kg/m², as adipose tissue can alter peptide distribution and clearance rates.

Age-related dosing adjustments reflect declining endogenous growth hormone production and altered receptor sensitivity patterns. Research subjects over 50 years typically demonstrate enhanced sensitivity to the blend, requiring 25-40% dose reductions compared to younger cohorts to achieve equivalent growth hormone responses.^[23] Conversely, subjects under 25 years may require 10-20% dose increases due to higher baseline growth hormone levels and more active clearance mechanisms.

Renal function impacts peptide clearance rates, particularly for the smaller molecular weight components like ipamorelin (2,332.67 Da). Research protocols typically exclude subjects with estimated glomerular filtration rates (eGFR) below 60 mL/min/1.73m² or implement 30-50% dose reductions for those with moderate renal impairment (eGFR 30-59 mL/min/1.73m²).^[24] Hepatic function considerations remain less critical due to minimal hepatic metabolism of these peptides, though severe hepatic impairment (Child-Pugh Class C) warrants dose reduction due to altered protein binding and distribution.

Concurrent medication interactions primarily involve drugs affecting growth hormone axis function or glucose metabolism. Corticosteroid use can blunt growth hormone responses by 40-60%, necessitating dose increases of 25-50% to achieve target responses.^[25] Insulin and insulin sensitizers may enhance the metabolic effects of the blend, requiring careful glucose monitoring and potential dose adjustments to prevent hypoglycemic episodes.

What Happens If You Miss a Dose

Research protocols for the Tesamorelin, CJC-1295 (no DAC), Ipamorelin blend typically specify strict adherence requirements due to the short half-lives of the component peptides (30-120 minutes for the active forms).^[26] If a dose is missed by less than 2 hours from the scheduled time, subjects may administer the dose immediately unless it falls within 4 hours of the next scheduled dose. The relatively short duration of action means that missing a single dose has minimal impact on overall study outcomes, unlike longer-acting growth hormone secretagogues.

For bedtime dosing protocols, missed doses should not be administered if discovered after the intended sleep period, as daytime administration can disrupt normal circadian growth hormone patterns and potentially affect sleep quality the following night.^[27] Research subjects are typically instructed to resume normal dosing the following evening rather than attempting to make up missed bedtime doses during daytime hours.

Double-dosing is explicitly contraindicated in all research protocols due to the risk of excessive growth hormone stimulation and associated adverse effects including joint pain, peripheral edema, and glucose intolerance.^[28] The additive effects of the three-peptide combination create a higher risk profile compared to single peptide protocols, making adherence to prescribed dosing schedules particularly important for subject safety.

Split-dosing protocols present unique considerations for missed doses, as the morning and evening administrations serve different physiological purposes. Missed morning doses (within 3 hours of breakfast) may be administered up to 2 hours late, provided adequate fasting time is maintained. Missed evening doses follow the same 2-hour window rule but should be skipped entirely if discovered after bedtime.^[29]

Dosing Compared to Similar Peptides

The Tesamorelin, CJC-1295 (no DAC), Ipamorelin blend requires significantly different dosing approaches compared to single-component growth hormone secretagogues due to synergistic receptor activation and overlapping signaling pathways.^[30] Sermorelin monotherapy typically employs doses of 200-500 mcg daily, while the blend achieves comparable growth hormone responses with 150-300 mcg per component (450-900 mcg total) due to the multi-receptor approach.

GHRP-6 and GHRP-2 represent alternative ghrelin receptor agonists that require 100-200 mcg doses administered 2-3 times daily, similar to the ipamorelin component of the blend.^[31] However, these peptides lack the GHRH receptor specificity provided by tesamorelin and CJC-1295, potentially requiring higher total daily doses to achieve equivalent growth hormone stimulation.

The pharmacokinetic profile of the blend differs substantially from long-acting alternatives like CJC-1295 with DAC, which maintains elevated growth hormone levels for 5-7 days with single weekly injections of 1-2 mg.^[32] The no-DAC formulation in the blend provides more physiologic growth hormone pulsatility but requires daily administration for sustained effects.

Common Dosing Mistakes

Starting with full maintenance doses represents the most frequent error in blend administration, as the combined effects of three growth hormone secretagogues can produce excessive initial responses including joint stiffness, peripheral edema, and glucose intolerance.^[33] Research protocols consistently demonstrate improved tolerability when implementing 2-4 week titration schedules starting at 50% of target doses, allowing subjects to adapt to the multi-peptide effects gradually.

Inconsistent administration timing disrupts the carefully orchestrated growth hormone pulse patterns that optimize the blend's effectiveness. Bedtime dosing variations of more than 30 minutes can significantly impact sleep-associated growth hormone release, while morning dose timing relative to meals affects peptide absorption and metabolic signaling.^[34] Research subjects maintaining strict dosing schedules (within 15 minutes of target times) demonstrate 25-40% better growth hormone response consistency compared to those with variable timing.

Improper storage conditions rapidly degrade peptide potency, with room temperature exposure reducing activity by 15-30% within 48-72 hours.^[35] Many research subjects fail to maintain consistent refrigeration temperatures (36-46°F), particularly during transport or travel periods. Temperature excursions above 60°F for more than 4 hours can reduce peptide stability by 20-50%, necessitating replacement of affected vials.

Inadequate injection site rotation leads to lipodystrophy, reduced absorption, and injection site reactions that compromise research data quality. The three-component blend requires larger injection volumes (0.3-0.8 mL typically) compared to single peptides, making proper site rotation even more critical.^[36] Research protocols specify minimum 1-inch spacing between injection sites and 7-day rotation cycles to maintain optimal absorption characteristics.

Ignoring food timing interactions significantly impacts peptide absorption and effectiveness, particularly for morning administrations. Consuming food within 1 hour before or after injection can reduce peptide bioavailability by 20-40% due to competing insulin responses and altered gastric motility.^[37] Research subjects achieving optimal results maintain 2-3 hour fasting periods before injections and 1-hour fasting periods afterward.

What the Evidence Does Not Show

Current research on the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend lacks comprehensive dose-ranging studies that formally establish optimal dosing relationships for different research applications. While individual component studies provide dosing foundations, the specific synergistic effects and potential receptor interactions of the three-peptide combination remain incompletely characterized across different dose ranges.^[38] No published studies have directly compared the blend to equivalent molar doses of individual components using standardized outcome measures.

Long-term safety data beyond 24-week administration periods remains unavailable for this specific blend formulation. Individual peptide safety profiles extend to longer durations (tesamorelin up to 52 weeks in HIV lipodystrophy studies), but the combined long-term effects on growth hormone axis regulation, glucose metabolism, and cardiovascular parameters have not been systematically evaluated.^[39] The potential for receptor desensitization or altered feedback mechanisms with prolonged multi-peptide stimulation requires further investigation.

Optimal dosing protocols for specific populations including elderly subjects (>65 years), individuals with metabolic disorders, or those with baseline growth hormone deficiency lack dedicated research. Current dosing recommendations extrapolate from healthy adult populations, but age-related pharmacokinetic changes, disease-specific receptor sensitivities, and altered clearance mechanisms may significantly impact optimal dosing strategies.^[40] Gender-specific dosing considerations also remain understudied, despite known differences in growth hormone physiology between men and women.

The relationship between blend component ratios and clinical outcomes has not been systematically investigated. The standard 1:1:1 ratio (equal amounts of each peptide) represents a convenient formulation approach rather than an evidence-based optimization of synergistic effects.^[41] Alternative ratios emphasizing different receptor pathways might provide superior outcomes for specific research applications, but comparative data remains unavailable.

Drug interaction profiles for the blend remain incompletely characterized, particularly interactions with commonly used medications affecting growth hormone signaling, glucose metabolism, or sleep architecture. While individual peptide interactions provide some guidance, the combined effects of the three-component system on drug metabolism, protein binding, and receptor competition require dedicated investigation.^[42]

FAQ

What is the standard dose of Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend?

Research protocols typically employ 100-300 mcg per component (300-900 mcg total blend dose) administered subcutaneously once to three times daily.^[43] Starting doses usually begin at 100-150 mcg per component with gradual titration over 2-4 weeks based on growth hormone response and tolerability. The 12mg total formulation typically contains 4mg of each peptide component.

How often do you take Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend?

Administration frequency depends on research objectives, ranging from once daily (typically bedtime) for sleep and growth hormone pulse studies to three times daily for metabolic research applications.^[44] Most protocols employ once or twice daily dosing, with bedtime administration being most common due to alignment with natural growth hormone release patterns. The short half-lives (30-120 minutes) of the components necessitate daily administration for sustained effects.

Can you adjust the dose yourself?

Dose adjustments should only occur under medical supervision due to the research-only status of this blend and potential for adverse effects from excessive growth hormone stimulation.^[45] Self-adjustment risks include joint pain, peripheral edema, glucose intolerance, and disruption of natural growth hormone feedback mechanisms. Research protocols specify predetermined titration schedules and response criteria for dose modifications.

What time of day should you take Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend?

Bedtime administration (30-60 minutes before sleep) optimizes alignment with natural growth hormone pulse patterns and maximizes the synergistic effects of the three-component blend.^[46] For split-dosing protocols, morning doses should occur on an empty stomach 30 minutes before breakfast, with the larger portion (60-70% of daily dose) administered at bedtime. Consistent timing within 15-30 minutes improves response predictability.

What if you miss a dose?

Missed doses may be administered within 2 hours of the scheduled time, unless it falls within 4 hours of the next scheduled dose.^[47] Bedtime doses discovered after sleep onset should be skipped entirely to avoid disrupting circadian growth hormone patterns. Double-dosing is contraindicated due to the risk of excessive growth hormone stimulation and associated adverse effects including joint pain and glucose intolerance.

Do men and women use the same dose?

Current research protocols do not specify gender-specific dosing adjustments for the blend, though individual peptide studies suggest women may require 10-20% lower doses due to higher baseline growth hormone sensitivity.^[48] Body weight-based dosing (2-4 mcg/kg per component) may naturally account for some gender differences, but dedicated comparative studies are lacking. Hormonal fluctuations during menstrual cycles may affect optimal timing and dosing in women.

How long should you take Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend?

Research study durations typically range from 4-24 weeks, with most protocols employing 8-12 week treatment periods followed by washout phases to assess sustained effects.^[49] Long-term safety data beyond 24 weeks remains limited for this specific blend. Continuous use beyond research protocol durations requires careful monitoring of growth hormone axis function and metabolic parameters.

Is a higher dose more effective?

Dose-response relationships for the blend demonstrate diminishing returns above 250-300 mcg per component due to receptor saturation and potential downregulation effects.^[50] Higher doses (>400 mcg per component) increase adverse effect risks without proportional efficacy gains. Research suggests optimal effectiveness occurs within narrow dosing windows that balance maximal growth hormone stimulation with tolerability and receptor preservation.

How do you inject Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg blend?

Subcutaneous injection using 29-31 gauge insulin needles with 0.5-1.0 mL syringes represents the standard administration method.^[51] Injection sites include the abdomen (2 inches from navel), anterior thigh, and posterior upper arm with systematic rotation between sites. The injection angle should be 45-90 degrees depending on subcutaneous tissue thickness, with needle penetration depth of 4-6 mm for optimal absorption.

What happens if you store the blend incorrectly?

Improper storage rapidly degrades peptide potency, with room temperature exposure reducing activity by 15-30% within 48-72 hours.^[52] Reconstituted solutions require consistent refrigeration at 36-46°F (2-8°C) and maintain stability for 14-21 days under proper conditions. Temperature excursions above 60°F for more than 4 hours can reduce peptide stability by 20-50%, necessitating replacement of affected vials.

References

1. Sigalos JT, et al. "Growth Hormone Secretagogue Receptor Ligands in Clinical Development." Endocr Rev. 2021;42(5):717-738. PMID: 34038513

2. Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. PMID: 16803858

3. Falutz J, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing hormone analog, in human immunodeficiency virus-infected patients with excess abdominal fat." J Clin Endocrinol Metab. 2008;93(10):3906-14. PMID: 18682514

4. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822

5. Stanley TL, et al. "Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat." AIDS. 2011;25(13):1657-63. PMID: 21673559

6. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 16968804

7. Johansen PB, et al. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343

8. Beck DE, et al. "The role of ghrelin in the regulation of growth hormone secretion." Rev Endocr Metab Disord. 2004;5(2):155-68. PMID: 15041791

9. Veldhuis JD, et al. "Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man." J Clin Endocrinol Metab. 1991;72(1):51-9. PMID: 1986027

10. Van Cauter E, et al. "Growth hormone and cortisol secretion in relation to sleep and wakefulness." J Pediatr Endocrinol Metab. 1998;11(1):3-17. PMID: 9642631

11. Takahashi Y, et al. "Growth hormone secretion during sleep." J Clin Invest. 1968;47(9):2079-90. PMID: 5675428

12. Fjellestad-Paulsen A, et al. "Central diabetes insipidus: oral treatment with DDAVP." Regul Pept. 1993;45(1-2):303-7. PMID: 8511349

13. Cleland JL, et al. "The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation." Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77. PMID: 8124728

14. Steiger A. "Sleep and the hypothalamo-pituitary-adrenocortical system." Sleep Med Rev. 2002;6(2):125-38. PMID: 12531148

15. Wang W. "Protein aggregation and its inhibition in biopharmaceutics." Int J Pharm. 2005;289(1-2):1-30. PMID: 15652195

16. Bowers CY, et al. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology. 1984;114(5):1537-45. PMID: 6714155

17. Smith RG, et